PREDI-LYNCH
A project for: European Union (Horizon Europe program)
BRIEF
The Challenge
Lynch syndrome (LS) is the most common hereditary cancer predisposition, significantly increasing the lifetime risk of colorectal, endometrial, and several other cancers. Yet LS has historically been underfunded and underserved, with only a small fraction of carriers identified and under surveillance. It is the most common monogenic hereditary cancer predisposition syndrome worldwide. LS affects 1 in 440 people of European ancestry. However, many are unaware of their risk, and only 5% of the 2 million estimated LS carriers in Europe are under cancer surveillance.
Existing methods for early detection and monitoring are invasive, costly, and often inadequate, leading to delayed diagnoses, unnecessary cancers, and preventable deaths.
FOCUS
The Approach
PREDI-LYNCH sets out to make a difference for people with Lynch syndrome (LS) by developing and implementing novel, non-invasive early detection methods for colorectal, endometrial and urothelial cancers in patients with Lynch syndrome.
The research team addresses an unmet medical need in providing an innovative approach to biomarker discovery for early-stage cancers in Lynch syndrome patients. The project gathers leading European researchers, clinicians, biotech companies and patient advocates. Together they aim for setting new standards in early cancer detection for rapid upscaling, for clinical adoption across EU and globally. The project has potential to change clinical practice. By integrating genetic markers, family history, lifestyle factors, and advanced multi-omic biomarkers, the project aims to transform surveillance and prevention for LS carriers across Europe and beyond.
The project is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers).
CONCLUSIONS
The Envisioned Result
PREDI-LYNCH expects to deliver validated non-invasive liquid biopsy tests for early detection of cancers in Lynch syndrome carriers. By integrating multi-omic biomarker panels with AI-based risk prediction, the project will enable earlier diagnosis, more effective prevention strategies, and improved patient outcomes. Health care systems will gain cost-effective tools and evidence to support the integration of personalized cancer surveillance into routine care.
PREDICTBY
Our Role
PredictBy is responsible for multiple tasks in this project as experts in health technology assessment and scalability of the solution. Our role in the project consists of conducting the following tasks:
Conducting a cost-effectiveness and economic viability assessment to assess the impact of PREDI-LYNCH to improve the efficiency of health and care systems while improving quality of life.
Evaluating industrial upscaling of the test assays and platforms.